Home › Research › Mild cognitive impairment
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, Mengel D, Walsh DM et al.. Brain : a journal of neurology, 2020-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer's disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (median three samples per person, median time from first to last sample, 4.3 years). Preclinical (amyloid-β-positive cognitively unimpaired, n = 62) and prodromal (amyloid-β-positive mild cognitive impairment, n = 49) Alzheimer's disease had accelerated p-tau217 compared to amyloid-β-negative cognitively unimpaired (β = 0.56, P < 0.001, using linear mixed effects models) and amyloid-β-negative mild cognitive impairment patients (β = 0.67, P < 0.001), respectively. Mild cognitive impairment patients who later converted to Alzheimer's disease dementia (n = 40) had accelerated p-tau217 compared to other mild cognitive impairment patients (β = 0.79, P < 0.001). P-tau217 did not change in amyloid-β-negative participants, or in patients with mild cognitive impairment who did not convert to Alzheimer's disease dementia. For 80% power, 109 participants per arm were required to observe a slope reduction in amyloid-β-positive cognitively unimpaired (71 participants per arm in amyloid-β-positive mild cognitive impairment). Longitudinal increases in p-tau217 correlated with longitudinal worsening of cognition and brain atrophy. In summary, plasma p-tau217 increases during early Alzheimer's disease and can be used to monitor disease progression.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 62 participants. In the Swedish BioFINDER study, plasma p-tau217 increased over time in people with preclinical and prodromal Alzheimer's disease and in those with mild cognitive impairment who later converted to dementia, but it did not change in amyloid-negative participants or non-converters. This suggests p-tau217 could be used to monitor disease progression, but it is not a treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mattsson-Carlgren, N., Janelidze, S., Palmqvist, S., Cullen, N., Svenningsson, A. L., Strandberg, O., et al. (2020). Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain : a journal of neurology. https://doi.org/10.1093/brain/awaa286
Vancouver
Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain : a journal of neurology. 2020. doi:10.1093/brain/awaa286. PMID: 33068398.
BibTeX
@article{mattssoncarlgren2020-33068398,
author = {Mattsson-Carlgren, N. and Janelidze, S. and Palmqvist, S. and Cullen, N. and Svenningsson, A. L. and Strandberg, O. and Mengel, D. and Walsh, D. M. and others},
title = {{Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease}},
journal = {Brain : a journal of neurology},
year = {2020},
doi = {10.1093/brain/awaa286},
pmid = {33068398},
url = {https://doi.org/10.1093/brain/awaa286}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Preclinical (amyloid-β-positive cognitively unimpaired, n = 62) and prodromal (amyloid-β-positive mild cognitive impairment, n = 49) Alzheimer's disease had accelerated p-tau217 compared to amyloid-β-negative cognitively unimpaired (β = 0.56, P < 0.001, using linear mixed effects models) and amyloid-β-negative mild cognitive impairment patients (β = 0.67, P < 0.001), respectively.
- Mild cognitive impairment patients who later converted to Alzheimer's disease dementia (n = 40) had accelerated p-tau217 compared to other mild cognitive impairment patients (β = 0.79, P < 0.001).
Why it matters
In the Swedish BioFINDER study, plasma p-tau217 increased over time in people with preclinical and prodromal Alzheimer's disease and in those with mild cognitive impairment who later converted to dementia, but it did not change in amyloid-negative participants or non-converters. This suggests p-tau217 could be used to monitor disease progression, but it is not a treatment, cure, or prevention.
Study details
- Study designlongitudinal study
- Participants62
- Evidence strengthModerate
How this study scored 75/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | 4 / 4 | Brain: journal h-index 503 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 62 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 368 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 46.0 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 5 / 6 | Cited 21.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 49 other studies in this library |
| Still being cited | 4 / 4 | Cited 233 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33068398) |
| Free to read | 2 / 2 | Free to read |
| Total | 75 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
49 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Mild cognitive impairment from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.